biote Corp.

biote Corp. is a hormone optimization company that went public through a de-SPAC business combination with Haymaker Acquisition Corp. III, which traded on Nasdaq under the ticker HYAC. The SPAC was sponsored by Haymaker Group and completed its initial public offering in 2021, targeting the healthcare sector with a focus on hormone health. This 10-K annual report, filed with the SEC on April 7, 2022, covers the period during which the business combination with biote was advancing toward its close. biote's core business centers on training and supporting healthcare practitioners in bioidentical hormone replacement therapy across the United States. For complete filing history, sponsor backgrounds, and deal analytics, sign up for full data access on SpacDesk.